EBR Systems, Inc. · ASX:EBR
EBR Systems — Shareholder Meeting (May 2025)
10 slides from EBR Systems's shareholder meeting presentation, May 22, 2025
Slide 1: 2025 Annual Meeting of Stockholders Presentation of President & CEO
ASX ANNOUNCEMENT 22 May 2025 2025 Annual Meeting of Stockholders Presentation of President & CEO Sunnyvale, California; 22 May 2025: EBR Systems, Inc. (ASX: “EBR”, “EBR Systems”, or the “Company”), is pleased to provide the presentation of the President & CEO to be delivered at the Company’s virtual
Slide 2: Forward-Looking Statements
of the left ventricle is thought to be a potentially superior, more anatomically correct pacing location. WiSE technology enables cardiac pacing of the left ventricle with a novel cardiac implant that is roughly the size of a large grain of rice. The need for a pacing wire on the outside of the hear
Slide 3: AGM Presentation May 2025
For personal use only AGM Presentation MAY 2025
Slide 4: Year in review
Year in review August 2024 • Successfully submitted the final module of Premarket Approval (“PMA”) application for WiSE® CRT System (“WiSE”) to the U.S. Food and Drug For personal use only Administration (“FDA”) September 2024 • Successful US$34.0m / A$50.0m capital raise completed December 2024 • A
Slide 5: Investment highlights
DRAFT FOR DISCUSSION Investment highlights Developer of the world’s first and only leadless pacemaker for heart failure For personal use only High value market opportunity Pathways to market Defined Strategy FDA approval Multiple pathways Clear commercial Manufacturing Unique solution Large markets
Slide 6: Targeting a US$3.6bn initial addressable market
Targeting a US$3.6bn initial addressable market At commercial launch, EBR estimates an initial addressable market of ~US$3.6bn For personal use only Worldwide CRM Market Initial Addressable market (~US$3.6bn)(2) (~US$13.6bn)(1) Acute Lead Failure Leadless Upgrades Unable to implant CRT wire in a • P
Slide 7: Clear commercialization strategy in place
Clear commercialization strategy in place Breakthrough device designation provides multiple pathways for reimbursement For personal use only ü Eligibility for inpatient add-on payments confirmed by CMS (NTAP1), outpatient requirements are met, subject to CMS decision (TPT1). Both anticipated to comm
Slide 8: WiSE Reimbursement
WiSE Reimbursement EBR has multiple pathways for WiSE Reimbursement For personal use only Medicare Coverage Medicare In-patient Payment Medicare Out-patient Payment Transitional Coverage of Emerging New Technology Add-On Payment (NTAP) Transitional Pass-Through (TPT) Technologies (TCET) - Effective
Slide 9: Disclaimer
Disclaimer The material contained in this document is a presentation of general information about the activities of EBR Systems, Inc. (ASX:EBR) (ARBN 654 147 127) and its subsidiaries (“EBR”) current as at the date of this presentation. It should be read in conjunction with EBR’s periodic and contin
Slide 10: Contact us
For personal use only Contact us Company John McCutcheon President & CEO P: +1 408 720 1906 E: [email protected] Investors Harry Halstead Vesparum Capital P: +61 3 8582 4800 E: [email protected]